tiprankstipranks

Augmedix downgraded to In Line from Outperform at Evercore ISI

Evercore ISI downgraded Augmedix to In Line from Outperform with a price target of $1.50, down from $5, following an in-line Q1 print and “disappointing” guidance. Management pointed to “the realization of many of our risks regarding the company and market,” including delayed decision making, increased competition, cannibalization of Live by Go Assist, and a delay in the HCA rollout, the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue